---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-24-000143"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2024-07-25T23:59:59+00:00"
generated_at: "2026-05-31T16:09:51.520011+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dexcom Q2 rev $1.004B (+15%); GAAP EPS $0.35; lowers FY rev guidance to $4.00-4.05B

## Summary
- Revenue $1.004B (+15% YoY); US +19%, intl +7% reported; organic growth 16%.
- GAAP EPS $0.35, Non-GAAP EPS $0.43; GAAP operating income $158.0M (15.7% margin).
- FY2024 revenue guidance lowered to ~$4.00-4.05B (11-13% organic); Q3 rev guidance $975M-$1.00B.
- Announces $750M share repurchase program authorized through June 30, 2025.
- CEO Kevin Sayer acknowledges execution shortfall but cites long-term growth opportunity.

## SEC filing metadata
- accession: 0001093557-24-000143
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2024-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000143/0001093557-24-000143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000143/dxcm-20240725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-24-000143
- JSON: https://secwatch.observer/filing/0001093557-24-000143.json
- Plain text: https://secwatch.observer/filing/0001093557-24-000143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.